{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-328716","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2026-07-31T20:31:37+00:00","discovered_at":"2026-07-31T20:33:00.306689+00:00","generated_at":"2026-07-31T20:33:12.576620+00:00","sec_items":["3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galera completes $350M PIPE financing; merger with Obsidian expected to close Aug 3, 2026","bullets":["Closed $350M PIPE sale of Series C Preferred Stock to qualified investors on July 31, 2026.","Merger with Obsidian expected to close August 3, 2026, subject to customary conditions.","Pre-Closing Distribution of CVRs to common stockholders: record date July 31, distribution date Aug 6.","Each CVR entitles holder to net proceeds from future disposition of tilarganine and GC4711/GC4419 assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-328716","json":"https://secwatch.observer/filing/0001193125-26-328716.json","markdown":"https://secwatch.observer/filing/0001193125-26-328716.md","text":"https://secwatch.observer/filing/0001193125-26-328716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526328716/0001193125-26-328716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312526328716/d138144d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T20:33:12.576620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}